142 studies found for:    c-kit
Show Display Options
Rank Status Study
1 Terminated Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
Conditions: cKIT-positive Solid Tumors;   AML
Intervention: Drug: LOP628
2 Recruiting Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
Condition: Ischemic Cardiomyopathy
Interventions: Biological: Mesenchymal Stem Cells (MSC);   Biological: Cardiac Stem Cells (CSC);   Biological: Placebo (Plasmalyte A)
3 Completed cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Condition: Melanoma
Intervention: Other: sequencing
4 Not yet recruiting The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy
Conditions: Hypersensitivity, Immediate;   Insect Bites and Stings;   Mastocytosis
5 Recruiting Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
Condition: Acute Myeloid Leukemia
Intervention: Drug: midostaurin (PKC412)
6 Completed
Has Results
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Condition: Melanoma
Interventions: Drug: Nilotinib;   Drug: DTIC
7 Recruiting Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Condition: Melanoma
Intervention: Drug: regorafenib
8 Completed A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
Condition: Leukemia
Intervention: Drug: Imatinib (Gleevec)
9 Completed
Has Results
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Condition: Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Imatinib mesylate
10 Recruiting A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
Condition: Metastatic Melanoma
Interventions: Drug: masitinib;   Drug: Dacarbazine
11 Withdrawn Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
Condition: Metastatic Solid Tumors.
Intervention: Drug: Glivec
12 Not yet recruiting The Transendocardial Autologous Cells (hMSC or hMSC and hCSC) in Ischemic Heart Failure Trial (TAC-HFT II)
Conditions: Chronic Ischemic Left Ventricular Dysfunction;   Myocardial Infarction
Interventions: Drug: Autologous hMSCs;   Drug: Autologous Human C-Kit CSCs II;   Drug: Placebo
13 Terminated Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: NOVE-HiDAC;   Drug: Nilotinib
14 Active, not recruiting Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Condition: Leukemia
Interventions: Drug: imatinib mesylate;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: biopsy
15 Unknown  A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: nilotinib
16 Unknown  Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
17 Active, not recruiting Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
Condition: Asthma
Interventions: Drug: Imatinib mesylate;   Drug: Placebo
18 Completed
Has Results
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Conditions: Sarcoma;   Gastrointestinal Stromal Tumors
Intervention: Drug: Imatinib mesylate (Glivec)
19 Recruiting Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Condition: Gastrointestinal Stromal Tumour (GIST)
Intervention: Drug: regorafenib
20 Completed Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Conditions: Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach;   Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years